Coronary Drug-Coated Balloons for De Novo and In-Stent Restenosis Indications

Figures

• 

  Figure 1. Kaplan-Meier estimates of the cumulative probabilities of major adverse cardiac events in the 2 study groups during 3 years for the full-analysis set of the BASKET-SMALL 2 trial.63 DCB, drug-coated balloon; DES, drug-eluting stent; HR, hazard ratio.

• 

  Figure 2. Kaplan-Meier estimates of the device-oriented primary composite end point (cardiac death, target vessel myocardial infarction, target lesion thrombosis, or target lesion revascularization) of the ISRA DESIRE 3 trial.117 DCB, drug-coated balloon; DES, drug-eluting stent; PB, plain balloon.

• 

  Figure 3. Primary efficacy and safety end point risk of the DAEDALUS patient-level meta-analysis in clinical trials comparing DCB and DES in in-stent restenosis (ISR).124 BMS, bare-metal stent; DCB, drug-coated balloon; DES, drug-eluting stent.

• 

  Central Illustration. DCB-only treatment algorithm according to the international DCB consensus group.91 DCB, drug-coated balloon; DES, drug-eluting stent; FFR, fractional flow reserve; ISR, in-stent restenosis; IVUS, intravascular ultrasound; OCT, optical coherence tomography; PCI, percutaneous coronary intervention.